

2015 No. 10 (W.)

**THE NATIONAL HEALTH
SERVICE (WALES) ACT 2006**

**The Pharmaceutical Services
(Advanced and Enhanced Services)
(Wales) (Amendment) Directions
2015**

Made 30 March 2015

Coming into force 1 April 2015

The Welsh Ministers, in exercise of the powers conferred on them by sections 12(3), 81, 82, 203(9) and (10) and 204(1) of the National Health Service (Wales) Act 2006⁽¹⁾, give the following Directions:

Title, commencement and interpretation

1.—(1) The title of these Directions is the Pharmaceutical Services (Advanced and Enhanced Services) (Wales) (Amendment) Directions 2015.

(2) These Directions come into force on 1 April 2015.

(3) In these Directions, “the principal Directions”, means the Pharmaceutical Services (Advanced and Enhanced Services) (Wales) Directions 2005⁽²⁾.

Amendment to direction 3 of the principal Directions

2.—(1) Paragraph (6) of direction 3 (Advanced Services: Medicines Use, Review and Prescription Intervention Service) of the principal Directions is amended as follows.

(2) In sub-paragraph (l) for “50%” substitute “70%”.

(3) For sub-paragraph (p) substitute—

(1) 2006 c.42.

(2) The Pharmaceutical Services (Advanced and Enhanced Services) (Wales) Directions 2004 have been amended by 2006 No. 88, 2008 No. 11, 2011 No. 41, 2013 No. 7 and 2014 No. 15.

“(p) The chemist must obtain from each patient to whom the chemist provides MUR services consent to receive all those services, which amongst other matters indicates that the patient has either consented or does not consent to particular information, relating to MUR services provided to the patient, being handled in the manner specified by the Welsh Ministers (for example, for the purposes of post payment verification).”

(4) After sub-paragraph (p) insert—

“(pa) The chemist—

- (i) must maintain a record of any consent obtained under sub-paragraph (p),
- (ii) must not provide MUR services to a patient unless the patient has consented to receive those services in accordance with sub-paragraph (p), and
- (iii) may only handle particular information in the manner for which the patient has provided consent in accordance with sub-paragraph (p).

Amendment to direction 4 of the principal Directions

3.—(1) Paragraph (1) of direction 4 (Enhanced Services) of the principal Directions is amended as follows.

(2) After sub-paragraph (s) insert the following sub-paragraphs—

- “(t) an anti-viral collection service, the underlying purpose of which is for the chemist to supply anti-viral medicines, in accordance with regulation 247 of the Human Medicines Regulations 2012(1) (Exemption for supply in event of or in anticipation of Pandemic disease), to patients for treatment or prophylaxis, and
- (u) an Emergency Supply Service, the underlying purpose of which is to ensure that in cases of urgency, patients, at their request have prompt access to drugs or appliances—

(1) S.I. 2012/1916

- (i) which have previously been prescribed for them in an NHS prescription but for which they do not have an NHS prescription, and
- (ii) where in the case of prescription only medicines the requirements of regulation 225(1) of the Human Medicines Regulations 2012 (emergency sale etc. by Pharmacist: at patient's request), are satisfied.”

Amendment to direction 6 of the principal Directions

4.—(1) Paragraph (1) of direction 6 (Advanced Services: Discharge Medicines Review Service ongoing conditions of arrangement) of the principal Directions is amended as follows.

(2) For sub-paragraph (f)(ii) substitute the following—

“(ii) obtaining from the patient to whom the chemist provides DMR services consent to receiving those services, which amongst other matters indicates that the patient has either consented or does not consent to particular information, relating to DMR services provided to the patient, being handled in the manner specified by the Welsh Ministers (for example, the purpose of post payment verification).”.

(3) After sub-paragraph (f)(ii) insert the following—


“(iia) The chemist—

- (aa) must maintain a record of any consent obtained under sub-paragraph (f)(ii),
- (bb) must not provide DMR services to a patient unless the patient has consented to receive those services in accordance with sub-paragraph (f)(ii), and
- (cc) may only handle particular information in the manner for which the patient has provided consent in accordance with sub-paragraph (f)(ii).”

Amendment to Schedule B of the principal Directions

5.—(1) In Schedule B (National Target Groups for MUR Services) to the principal Regulations , after paragraph 5 insert the following paragraph—

“6 Patients aged 85 of over who are prescribed six or more medicines.”

A handwritten signature in black ink that reads "Roger Walker". The signature is written in a cursive style with a large initial 'R'.

Signed by Professor Roger Walker, Chief
Pharmaceutical Officer under the authority of the
Minister for Health and Social Services, one of the
Welsh Ministers.

Dated: 30 March 2015